MORRISVILLE – New funding in the form of $7 million in A Series B fROUND will accelerate the commercialization of the automated and individualized poultry vaccination systems, SAYS Morrisville-based Applied LifeSciences & Systems, or ALSS.
The round was co-led by Merck Animal Health and Mountain Group Partners, and included an investment from Oval Park Capital, a Raleigh-based early-stage investment firm, which was also an early investor.
According to the company, its high-speed imaging, feature recognition, artificial intelligence, robotics, and microfluidics proprietary technologies are integrated in a system developed to address a significant challenge for the commercial poultry industry: successful, efficient vaccinations.
The system can vaccinate up to 100,000 chicks each hour.
“Our initial product line has successfully demonstrated targeting and vaccine delivery at the high speeds and accuracy needed to integrate and support improved bird performance within current commercial poultry operations,” said Ramin Karimpour, company founder and CEO. “We look forward to the successful commercialization and launch of our systems in 2022.”
The company notes prior funding from Merck Animal Health, the National Science Foundation, and the One North Carolina Small Business Program on its website, and is hiring a vice president of finance and a CAD Drafter.
Raleigh startup Applied LifeSciences & Systems lands $8M, Merck as investor
